Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tekia's presbyopia intraocular lens:

This article was originally published in Clinica

Executive Summary

Tekia has CE-marked for sale in Europe its accommodating intraocular lens for treating presbyopia. The implantable device uses the eye's ocular structures to shift the lens forward, enabling a person to see close up, and then shift back to the resting position so the person will see distant objects. In the US, the Irvine, California firm expects to submit to the FDA later this year an application to test the lens in clinical studies; to fund the FDA approval process the firm expects to pursue financing options and/or a strategic partner to provide additional resources. Tekia currently distributes in Europe and in certain South American countries its Kelman Duet refractive IOL for treating myopia and hyperopia in non-cataract patients.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT050643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel